Global Perspectives on Biomarker-Driven Therapeutic Strategies in Pancreatic Cancer

Global Perspectives on Biomarker-Driven Therapeutic Strategies in Pancreatic Cancer

Thursday, January 14, 2021
Webinar -- 6:00 PM CET
https://www.clinicaloptions.com/GIPancreatic2021Join1

Agenda

  • BRCA and Homologous Repair Deficiency in PDAC – Dr. Philip
    • Identifying patients with germline mutations
    • Deleterious germline mutations in the homologous repair process
    • Epidemiology of germline mutations in PDAC
    • Evaluating “BRCAness”
    • Role of somatic mutations within the homologous repair pathway
  • Therapeutic Approaches for PDAC Harboring BRCA Mutations and HRD– Professor Arnold
    • Cytotoxic DNA Damaging agents
    • PARP inhibition as maintenance therapy
    • Combination PARP inhibitor (PARPi) with other agents
  • Panel Discussion: Clinical Pearls and Treatment Challenges
    • Two patient cases on:
      • Toxicities
      • Uncommon molecular workup
    • Future strategies around DNA repair

Faculty

Faculty
Dirk Arnold, MD, PhD

Professor of Medicine
University Hamburg
Director
Asklepios Tumorzentrum Hamburg 
Head of Department
Oncology, Hematology and Rheumatology
AK Altona
Paul-Ehrlich-Strasse 1
22763 Hamburg, Germany

Faculty
Philip Philip, MD, PhD, FRCP

Professor of Medicine
Wayne State University School of Medicine
Clinical Professor of Oncology
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, USA

This educational activity is not certified for CME/CE credit

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate current and emerging therapies into the treatment of patients with pancreatic cancer.

Target Audience
This educational program is intended for medical oncologists and other healthcare providers globally who treat patients with pancreatic cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Assess BRCA1/2 and other alterations leading to homologous repair deficiency in patients with advanced pancreatic ductal adenocarcinoma
  • Apply current data and expert recommendations to optimally use platinum-based chemotherapy in patients newly diagnosed unresectable pancreatic ductal adenocarcinoma and germline BRCA mutations
  • Plan therapeutic strategies for patients with advanced pancreatic ductal adenocarcinoma harboring BRCA1/2 or other DNA damage response mutations
  • Evaluate available data and ongoing clinical trials on emerging and investigational therapies for pancreatic ductal adenocarcinoma
  • Incorporate strategies to effectively identify and manage disease-related and treatment-related adverse events to support quality of life and continuation of therapy

Accreditation

This educational activity is not certified for CME/CE credit.